| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| Targets |
Vitamin B1, Thiamine, Transketolase[1].
|
|---|---|
| ln Vitro |
Oxythiamine chloride hydrochloride (0-40 μM, 2 days) reduces MIA PaCa-2 cell viability (IC50: 14.95 μM)[1]. In MIA PaCa-2 cells, oxythiamine chloride hydrochloride (0-500 μM, 48 hours) suppresses the expression of 14-3-3 protein beta/alpha [1]. A549 cell proliferation is inhibited by oxythiamine chloride hydrochloride (0.1-100 μM, 6-48 h)[3]. The apoptosis of A549 cells is induced by oxythiamine chloride hydrochloride (0.1-100 μM, 24 h)[3]. [3]. Lewis lung cancer (LLC) cell invasion and migration are inhibited by oxythiamine chloride hydrochloride (0–20 μM) (IC50: 8.75 μM)[4].
|
| ln Vivo |
In Ehrlich ascites host mice, oxythiamine chloride hydrochloride (100–500 mg/kg, intraperitoneal for 4 days) suppresses tumor growth [2]. In mice implanted with (sc) LLC cells, oxythiamine chloride hydrochloride (250 or 500 mg/kg once day for 5 weeks) reduces tumor cell metastasis via blocking MMPs [4].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MIA PaCa-2 cells Tested Concentrations: 0-40 μM Incubation Duration: 2 days Experimental Results: Inhibited cell viability with an IC50 of 14.95 μM. Western Blot Analysis[1] Cell Types: MIA PaCa-2 cells Tested Concentrations: 0, 5, 50, 500 μM Incubation Duration: 48 h Experimental Results: Inhibited 14-3-3 protein beta/ alpha expression, and increased alpha-enolase. |
| Animal Protocol |
Animal/Disease Models: Ehrlich's ascites tumor hosting mice[2]
Doses: 100-500 mg/kg Route of Administration: ip, 4 days Experimental Results: Inhibited tumor growth by 43% at 300 mg/kg and 84% at 500 mg/kg. |
| References |
[1]. Wang J, et al. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol. 2013 Jul 27;2:18.
[2]. Raïs B, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999 Jul 30;456(1):113-8. [3]. Bai L, et al. A dose- and time-dependent effect of oxythiamine on cell growth inhibition in non-small cell lung cancer. Cogn Neurodyn. 2022 Jun;16(3):633-641. [4]. Yang CM, et al. The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis. 2010 May;27(5):341-9. |
| Molecular Formula |
C12H17CL2N3O2S
|
|---|---|
| Molecular Weight |
338.25
|
| CAS # |
614-05-1
|
| Related CAS # |
Oxythiamine;136-16-3
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CC1=C(CCO)SC=[N+]1CC2=C(N=C(C)N=C2)N=O.Cl.[Cl-]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (147.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9564 mL | 14.7820 mL | 29.5639 mL | |
| 5 mM | 0.5913 mL | 2.9564 mL | 5.9128 mL | |
| 10 mM | 0.2956 mL | 1.4782 mL | 2.9564 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
